Novimmune is known for its development of a proprietary next-generation platform for the creation of monoclonal and bi-specific antibodies. This innovative approach to discovery and development has led to the creation of sixteen mono- and bi-specific human antibodies since the company was established in 1998.

To date, Novimmune has brought six monoclonal antibodies, as well as a first bispecific antibody based on its proprietary format, to clinical development stage. Notable amongst these is the anti-IFNy monoclonal antibody, emapalumab, developed as a treatment for primary Haemophagocytic Lymphohistiocytosis (HLH), which was approved by the Food and Drug Administration for the use in this indication and still in development for secondary HLH.

Prior to the development of emapalumab, no drug had ever been studied for the treatment of this disease nor had any drug been approved by regulatory authorities. In 2019, Novimmune successfully divested emapalumab, the anti-IFNy monoclonal antibody, Gamifant®, and related assets to SOBI.

Novimmune recently moved to state-of-the-art facilities located in Geneva and operates under the brand “Light Chain Bioscience” to develop its bi- and multi-specific antibody technologies and associated programs, focusing on immuno-oncology and other indications.

Today it employs around 60 people spanning 7 different nationalities. The team is highly skilled in discovery, preclinical research, and manufacturing and clinical research.

Founded by the renowned immunologist, Professor Bernard Mach MD PhD, privately-owned Novimmune is a leading light in the discovery and development of fully-human, antibody-based drugs used to fight autoimmune and inflammatory diseases and cancer.